[Clinical evaluation of the therapeutic efficacy of a new antiphlogistic and mucus-regulating drug, guaimesal, in acute and chronic bronchopneumopathies].
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000031:analogs & derivatives / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy*; D001996:Bronchopneumonia / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004146:Dioxanes / Q000627:therapeutic use*; D004147:Dioxins / Q000627:therapeutic use*; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000893:Anti-Inflammatory Agents; D004146:Dioxanes; D004147:Dioxins; D005100:Expectorants; C043484:guaimesal; D001241:Aspirin; C023557:guacetisal
Valutazione clinica dell'afficacia terapeutica di un nuovo farmaco ad attività antiflogistica e mucoregolatrice, il guaimesal, nelle broncopneumopatie acute e croniche.